Jiménez-Mejías M E, Guerrero-Montávez J M, Aznar-Martín A
Rev Esp Fisiol. 1984 Jun;40(2):133-9.
The administration of 0.00011 mg/g weight/day of bromocriptine (CB154) for 7 days to Wistar rats, improved the peripheral glucose uptake without significant changes in plasma insulin level, during the intravenous glucose tolerance test (0.33 g/kg). The mode of the bromocriptine action on binding of 125I insulin to erythrocyte insulin receptors has been evaluated. The total number of sites was greater with bromocriptine (513.1 +/- 124.1 pM/1,CB154 815.6 +/- 107.9 pM/l) (p less than 0.01). The high affinity/low capacity compound of insulin receptor, in CB154 rats (51.8 +/- 16.8 pM/l) was higher than in normal rats (18.3 +/- 8.9 pM/l) (p less than 0.005). Additional studies indicated that CB154 had no effect on the rate of association and dissociation of 125I insulin from rats erythrocyte insulin receptors. The degradation of insulin or the erythrocyte receptor sites do not change, after the treatment with CB154.
给Wistar大鼠按0.00011毫克/克体重/天的剂量注射溴隐亭(CB154),持续7天,在静脉葡萄糖耐量试验(0.33克/千克)期间,可改善外周葡萄糖摄取,而血浆胰岛素水平无显著变化。已评估了溴隐亭对125I胰岛素与红细胞胰岛素受体结合的作用方式。溴隐亭处理组的位点总数更多(513.1±124.1皮摩尔/升,CB154为815.6±107.9皮摩尔/升)(p<0.01)。CB154大鼠胰岛素受体的高亲和力/低容量复合物(51.8±16.8皮摩尔/升)高于正常大鼠(18.3±8.9皮摩尔/升)(p<0.005)。进一步研究表明,CB154对125I胰岛素与大鼠红细胞胰岛素受体的结合和解离速率没有影响。用CB154处理后,胰岛素或红细胞受体位点的降解没有变化。